(NASDAQ: TNGX) Tango Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Tango Therapeutics's earnings in 2026 is -$123,720,000.On average, 14 Wall Street analysts forecast TNGX's earnings for 2026 to be -$243,490,231, with the lowest TNGX earnings forecast at -$259,423,911, and the highest TNGX earnings forecast at -$230,153,151. On average, 14 Wall Street analysts forecast TNGX's earnings for 2027 to be -$287,649,286, with the lowest TNGX earnings forecast at -$368,481,096, and the highest TNGX earnings forecast at -$219,530,698.
In 2028, TNGX is forecast to generate -$336,512,570 in earnings, with the lowest earnings forecast at -$436,228,742 and the highest earnings forecast at -$240,775,604.